Results 91 to 100 of about 48,364 (325)

Clinical Impact of Switching or Continuation of Apixaban or Rivaroxaban among Patients with Non-Valvular Atrial Fibrillation

Journal of Clinical Medicine
Background: Real-world evidence on direct oral anticoagulant outcomes among Non-Valvular Atrial Fibrillation (NVAF) patients is limited. We aimed to evaluate stroke/systemic embolism (SE) and major bleeding (MB) risks among NVAF patients continuing or ...
S. Deitelzweig, A. Kang, Jenny Jiang, C. Gao, Xuemei Luo, N. Atreja, Stella Han, D. Cheng, Saarusri R Loganathan, G. Lip   +9 more
semanticscholar   +1 more source

Quantitative Model‐Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation

Clinical Pharmacology &Therapeutics, EarlyView.
Milvexian, an activated factor XI inhibitor, is being evaluated in the LIBREXIA phase III program for the prevention of thrombotic events, including in patients with atrial fibrillation (LIBREXIA AF). To guide the selection of a phase III dose regimen for LIBREXIA AF, two main approaches were used: (1) population pharmacokinetics and exposure–response ...
Wangda Zhou, Emily Bozenhardt, Gregory E. Alexander, Matthew L. Zierhut, Samira Merali, Antoinette Ajavon‐Hartmann, Peter Zannikos, Hyunmoon Back, EunYoung Suh, Navin Goyal, Mahesh N. Samtani, Alexei N. Plotnikov, Chandni Valiathan   +12 more
wiley   +1 more source

Apixaban in low‐weight patients with cancer‐associated thrombosis: A cross sectional study of drug levels

Research and Practice in Thrombosis and Haemostasis, 2021
Introduction Apixaban, a direct factor Xa inhibitor, has been shown to be at least as safe and probably more effective than dalteparin for the treatment of cancer‐associated thrombosis (CAT) as reported in the ADAM‐VTE and Caravaggio studies, which ...
Verónica Bravo Villa, Job Romero, Eunice Rojas‐Zaldivar, Martha Cervantes, María del Rosario Villa‐Márquez, Patricia Baz, Gabriela Cesarman‐Maus   +6 more
doaj   +1 more source

Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients. [PDF]

, 2012
SummaryAnticoagulation therapy for the prevention of venous thromboembolic events is indicated in patients after major orthopaedic surgery and in hospitalised acutely ill medical patients, who have a high or moderate risk of venous thromboembolism (VTE),
Ageno W, Spyropoulos AC, Turpie AG
core   +1 more source

Nonsteroidal Anti‐Inflammatory Drugs and Risk of Gastrointestinal Bleeding: A Systematic Review and Meta‐Analysis

Clinical Pharmacology &Therapeutics, EarlyView.
Nonsteroidal anti‐inflammatory drugs (NSAIDs) are widely used for pain and inflammation but are associated with gastrointestinal (GI) bleeding. While this risk is well established, most studies evaluate NSAIDs as a homogenous class, limiting clinical decision‐making based on individual agent safety.
Abdelrahman G. Tawfik, Ainhoa Gomez‐Lumbreras, Guilherme Del Fiol, Kensaku Kawamoto, Katy E. Trinkley, Thomas Reese, Aubrey Jones, Daniel C. Malone   +7 more
wiley   +1 more source

Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation -a look beyond the excellent results [PDF]

, 2012
In this overview we address the three phase III studies that compared new oral anticoagulants (dabigatran, rivaroxaban and apixaban) with warfarin in the setting of stroke prevention in atrial fibrillation.
Crippa, L, Falanga, A, Finazzi, G, Manotti, C., Marongiu, F, Moia, M, Palareti, G, Pengo, V, Poli, D, Policarpo, D, SIRAGUSA, Sergio, TESTA, Silvia, Tiraferri, E, Tosetto, A, Tripodi, A   +14 more
core   +1 more source

Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events

Frontiers in Genetics, 2022
Apixaban is a direct oral anticoagulant, a factor Xa inhibitor, used for the prevention of ischemic stroke in patients with atrial fibrillation. Despite using recommended dosing a few patients might still experience bleeding or lack of efficacy that ...
S. Attelind, P. Hallberg, M. Wadelius, Anna-Karin Hamberg, A. Siegbahn, C. Granger, R. Lopes, J. Alexander, L. Wallentin, N. Eriksson   +9 more
semanticscholar   +1 more source

Clinical Implementation of Pharmacogenomics and Drug–Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow‐Up

Clinical Pharmacology &Therapeutics, EarlyView.
Overview of the implemented pharmacogenomics (PGx) process in clinical routine at the Robert Bosch Hospital: from patient enrollment via the hospital information system, DNA detection using a customized TaqMan OpenArray panel and qPCR for CNV assessment, to clinical translation of genotyping results into PGx guideline‐based recommendations using a ...
Roman Tremmel, Filippa Schreeck, Simon Jaeger, Severin Schricker, Elke Schaeffeler, Svitlana Igel, Daniela Steinberger, Manuel Pagitz, Jörg Latus, Markus Ketteler, Kerstin Bühl, Marc‐H. Dahlke, Hans‐Georg Kopp, Matthias Schwab   +13 more
wiley   +1 more source

Effective Apixaban removal using hemoadsorption during emergent open-heart surgery: a case report and narrative literature review

Journal of Cardiothoracic Surgery
Background The management of hemostasis in patients medicated with apixaban (Eliquis) undergoing emergency cardiac surgery is exceedingly difficult. The body’s natural elimination pathways for apixaban prove ineffective in emergency situations, and the ...
Vitor Mendes, Jaid Mamode, Jalal Jolou, Mourad Malki, Christoph Ellenberger, Mustafa Cikirikcioglu, Christoph Huber   +6 more
doaj   +1 more source

Electronic monitoring of adherence to once‐daily and twice‐daily direct oral anticoagulants in patients with atrial fibrillation: Baseline data from the SMAAP‐AF trial

Journal of Arrhythmia, 2021
Background Nonadherence diminishes the efficacy of direct oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation (NVAF). This report presents the baseline survey results regarding medication adherence among NVAF patients who were ...
Tsuyoshi Shiga, Toshimi Kimura, Noritoshi Fukushima, Yuji Yoshiyama, Kazunori Iwade, Fumiaki Mori, Yoichi Ajiro, Shoji Haruta, Yuichiro Yamada, Emi Sawada, Nobuhisa Hagiwara, the SMAAP‐AF investigators   +11 more
doaj   +1 more source